Clinical Trial Detail

A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Complete title: A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of

Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin

Lymphomas

Research Study Number	RG1005774
Principal Investigator	Ajay Gopal, MD
Phase	I

Look up trial at NIH

Research Study Description

This is a Phase 1 study of IGM-2323 in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage and a dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. IGM-2323 will be administered intravenously (IV).

Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number

RG1005774

Keywords: Lymphoma; Lymphoma, Non-Hodgkin (NHL); Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Marginal Zone

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019